Loading
Runs one of the world's largest phase 1 programmes and led trials that shaped head and neck cancer immunotherapy.
Lillian L. Siu is Director of the Phase I Program and holds the BMO Chair in Precision Cancer Genomics at the Princess Margaret Cancer Centre. She is a medical oncologist who runs one of the world's largest phase 1 programmes and led KEYNOTE and other immunotherapy studies that shaped head and neck cancer treatment. Her selected paper reports the CONDOR trial of durvalumab with or without tremelimumab in PD-L1-low or negative recurrent or metastatic head and neck squamous cell carcinoma. She pioneers ctDNA-guided early trials and is AACR president for 2025 to 2026.
Shares Princess Margaret Cancer Centre, Liquid biopsy (ctDNA).
Shares Princess Margaret Cancer Centre, Immune checkpoint inhibitors.
Shares Princess Margaret Cancer Centre, Liquid biopsy (ctDNA).
Shares Princess Margaret Cancer Centre, Immune checkpoint inhibitors.
Shares Princess Margaret Cancer Centre, Immune checkpoint inhibitors.